Street View: Danaher well positioned to navigate tough macro environment

Danaher DHR.N beat Wall Street estimates for first-quarter profit on Tuesday, and said it expects to incur additional tariff-related costs of about $350 million this year

Median PT of brokerages covering the stock is $246.50, per data compiled by LSEG

ABLE TO NAVIGATE TOUGH ENVIRONMENT

Leerink Partners ("outperform", PT:$230) says it sees DHR as the leader in the recurring revenue market of bioprocess tools

William Blair ("outperform") says Danaher is well insulated from broader macro headwinds (e.g., weaker U.S. academic and government market, slowdown in biotech funding, tariffs)

Evercore ISI ("outperform", PT:$230) says underlying order momentum and backlog build was a solid data point that suggests order patterns normalizing

RBC Capital Markets ("outperform," PT:$250) says DHR's positive Q1 results provides a much-needed piece of good news for the sector